$Actinium (ATNM.US)$SECuRE Trial Update: 92% of Pre-chemo Participants Experience Greater Than 35% Drop in PSA Levels Across All Cohorts. Cohort Expansion Phase Commences. PR Newswire 5 mins ago HIGHLIGHTS Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase (Phase II stage) of the SECuRE study. Based on the efficacy and safety assessment of all cohorts and the focus on earlier stages of treatment, the SRC confirmed...
$Actinium (ATNM.US)$NorthStar Medical Radioisotopes and YAP Therapeutics Enter Into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products Businesswire· 13 mins ago NorthStar to support the development of YAP Therapeutics' innovative radiolabeled productsThis collaboration merges the expertise and resources from both companies, including NorthStar's state-of-the-art facilitiesThe agreement guarantees that YAP Therapeutics will receive clinical trial-read...
$Actinium (ATNM.US)$SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement With Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player PR Newswire· 10 mins ago SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha-particleemittingradioisotope, actinium-225, for potential cancer treatm...
$Actinium (ATNM.US)$Not sure why this didn't pop up on the Moomoo news fees but it's back to another Phase 3 for their AML drug. Actinium Announces Publication Of Phase 3 SIERRA Results Of Iomab-B - Quick Facts Good lesson on the higher risks of biologics though. BLA (biologics license application) a relatively new classification (maybe 5 or so years?) meant to divert biologics from the NDA process that small molecule drugs go through. In practical terms,...
$Actinium (ATNM.US)$Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma September 05, 2024 08:00 AM Eastern Daylight Time!!! From this morning! BUT THIS ONE BELOW JUST WAS RELEASED VIA SEEKING ALPHA! NOT SURE IF THEY ARE MISPRINT OF DRUG? OR ANOTHER APPROVAL? Perspective gets FDA fast track status for radiopharmaceutical VMT101
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Actinium Stock Forum
Revolutionary Triple-Drug Combination Trial Targets Newly Diagnosed AML Patients
PR Newswire
5 mins ago
HIGHLIGHTS
Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase (Phase II stage) of the SECuRE study.
Based on the efficacy and safety assessment of all cohorts and the focus on earlier stages of treatment, the SRC confirmed...
Businesswire· 13 mins ago
NorthStar to support the development of YAP Therapeutics' innovative radiolabeled productsThis collaboration merges the expertise and resources from both companies, including NorthStar's state-of-the-art facilitiesThe agreement guarantees that YAP Therapeutics will receive clinical trial-read...
PR Newswire· 10 mins ago
SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha-particleemittingradioisotope, actinium-225, for potential cancer treatm...
Actinium Announces Publication Of Phase 3 SIERRA Results Of Iomab-B - Quick Facts
Good lesson on the higher risks of biologics though. BLA (biologics license application) a relatively new classification (maybe 5 or so years?) meant to divert biologics from the NDA process that small molecule drugs go through.
In practical terms,...
Actinium Pharmaceuticals Inc - Iomab-B Well Tolerated in Older Relapsed/Refractory Aml Patients
September 05, 2024 08:00 AM Eastern Daylight Time!!! From this morning! BUT THIS ONE BELOW JUST WAS RELEASED VIA SEEKING ALPHA! NOT SURE IF THEY ARE MISPRINT OF DRUG? OR ANOTHER APPROVAL?
Perspective gets FDA fast track status for radiopharmaceutical VMT101
No comment yet